S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company
focused on the development of innovative treatments for metabolic
disorders, including type 2 diabetes and non-alcoholic steatohepatitis
(NASH), announced today its results for the year ended December 31, 2018
and provided a corporate update.
"We made substantial progress advancing the Company in 2018. Our
significant accomplishments include signing an agreement with Roivant
Sciences for Imeglimin in the US, Europe and the rest of the world not
covered in the agreement with Sumitomo Dainippon Pharma, fully enrolling
all three Imeglimin Phase 3 TIMES trials with over 1,100 patients in
Japan, advancing PXL770 for the treatment of NASH and acquiring PXL065,
a second clinical-stage program for the treatment of NASH,” said Thomas
Kuhn, CEO of Poxel.
"This year will be very important for Poxel. There will be several
significant milestones that have the potential for substantial value
creation. For Imeglimin, key milestones include the announcement of
Phase 3 data results beginning early second quarter with the TIMES 1
results and further Phase 3 data from the TIMES 2 and TIMES 3 studies,
which will be reported on throughout 2019. In parallel to leading the
Phase 3 TIMES program, we have been working very closely with our
partner Sumitomo Dainippon Pharma in preparing for the Japanese New Drug
Application for Imeglimin for the treatment of type 2 diabetes, which is
a significant milestone targeted for 2020 with product launch
anticipated in 2021,” said Thomas Kuhn, CEO of Poxel.
"For our two clinical-stage programs for the treatment of NASH, key
milestones include, initiation of a Phase 2a program for PXL770, which
will include efficacy and safety assessment as well as a separate
pharmacokinetic and pharmacodynamic study. Data results from these
studies are anticipated to be announced beginning later this year,”
continued Thomas Kuhn. "For PXL065, we plan to initiate a pivotal Phase
2 program for the treatment of NASH in the fourth quarter or early 2020
following completion of the Phase 1 program mid-year to third quarter
Poxel 2018 Highlights
Imeglimin is the first orally available drug candidate that
simultaneously targets all three key organs affected by diabetes: the
pancreas, the liver and the muscles. It has completed Phase 1 and Phase
2 development in over 1,200 subjects in the U.S., Europe and Japan and
is in Phase 3 development in Japan. Over the course of 2018, Imeglimin
successfully completed several important milestones.
Strategic Partnership Signed for Imeglimin in the
U.S., Europe and Additional Countries Worldwide
The strategic agreement with Roivant for the development and
commercialization of Imeglimin in the U.S., Europe and additional
countries worldwide will support Imeglimin’s development and
commercialization in the U.S., Europe and other countries outside of
Poxel’s partnership with Sumitomo Dainippon Pharma.
To support the initiation of the Phase 3 program, activities in 2018
with Metavant, a subsidiary of Roivant, include an ongoing study in
type 2 diabetes patients with moderate-to-severe chronic kidney
disease, as well as manufacturing of the drug product for use in the
Phase 3 program.
The goal is for Metavant to initiate the Phase 3 program in 2019.
Progression of the Phase 3 TIMES Program
Referred to as TIMES (Trials of IMeglimin for Efficacy
and Safety), the Imeglimin Phase 3 program in Japan enrolled
three pivotal trials to evaluate Imeglimin’s efficacy and safety in
over 1,100 patients.
Phase 3 data results for the TIMES program are expected to be
announced in 2019 beginning with TIMES 1 top-line results, which are
expected early second quarter. The TIMES 3 16-week, double-blind,
placebo controlled, randomized part of the study is anticipated to
report top-line data mid-year and the TIMES 2 and full results from
the TIMES 3 trials are anticipated in the fourth quarter of 2019.
The TIMES 1 trial is a multicenter, double-blind, placebo-controlled,
randomized, monotherapy study in over 200 Japanese patients with type
2 diabetes. The TIMES 2 trial is an open-label study to assess the
long-term safety and efficacy of Imeglimin administered as a
monotherapy or combination therapy with existing hypoglycemic agents
in approximately 700 Japanese patients with type 2 diabetes. The TIMES
3 trial is a double-blind, placebo-controlled, randomized study with
an open-label extension period to evaluate the efficacy and safety of
Imeglimin in combination with insulin in over 200 Japanese patients
with type 2 diabetes and inadequate glycemic control on insulin
Data at the American Diabetes Association 78th
Data on Imeglimin’s effect on pancreatic beta-cell protection was
presented at the American Diabetes Association 78th
Scientific Sessions. Imeglimin was observed to protect and preserve
human beta-cells from cell death from fructose- and glucose-induced
toxicity by inhibiting mitochondrial Permeability Transition Pore
opening (mPTP). This data highlights Imeglimin’s potential to delay
type 2 diabetes disease onset and progression through the preservation
of beta-cell mass.
PXL770 is a first-in-class direct adenosine monophosphate-activated
protein kinase (AMPK) activator. AMPK plays a key role as a master
regulator of cellular energy and modifying its activity offers the
opportunity to pursue a wide range of indications to treat chronic
metabolic diseases, including diseases that affect the liver, such as
Preclinical proof-of-concept data presented at the Global NASH
Congress 2018 highlighted PXL770 as a novel therapeutic approach in
non-alcoholic fatty liver diseases (NAFLD), improving core disease
symptoms. PXL770 was observed to significantly reduce liver steatosis
and NAS score following eight weeks of treatment vs control and
significantly reduce expression of a panel of key genes associated
Data presented at the American Association for the Study of Liver
Diseases (AASLD) meeting in November 2018 showed a beneficial effect
for PXL770 on both the adipose tissue and liver through direct
activation of AMPK in a DIO-NASH model.
Data presented at the AMPK - From Mechanisms to New Therapies
Scientific Congress in October 2018 showed PXL770 was observed to have
a favorable pharmacokinetic, tolerability and safety profile in the
Phase 1 clinical program and demonstrated a favorable cardiac safety
profile in animal models.
The Phase 2a program for PXL770 is expected to begin during the first
quarter of 2019. The twelve-week Phase 2a efficacy and safety study
will measure the change in liver fat mass based on magnetic
resonance imaging-estimated proton density fat fraction (MRI-PDFF) and
assess the effects of PXL770 on key metabolic pathways involved in the
physiopathology of NASH, as well as safety and other metabolic and
non-metabolic parameters in approximately 100 patients who likely have
Also included in the Phase 2a program will be a separate
pharmacokinetic and pharmacodynamic study that is expected to be
initiated during the second quarter of 2019.
PXL065 (deuterium-stabilized R-pioglitazone) is a mitochondrial pyruvate
carrier (MPC) inhibitor. PXL065 is the R-stereoisomer (single isomer) of
On August 30, 2018, Poxel acquired from DeuteRx exclusive, worldwide
ownership of PXL065 (deuterium-stabilized R-pioglitazone), as well as
additional programs, including deuterated drug candidates for
metabolic, specialty and rare diseases. PXL065 is a clinical-stage
program for the treatment of NASH.
Poxel paid DeuteRx an upfront payment composed of EUR 6.8 million (USD
8 million) in cash plus 1.29 million in new ordinary shares of Poxel
common stock, representing 4.99 percent of Poxel’s issued capital.
DeuteRx is also eligible to receive development, regulatory and
sales-based milestone payments and royalties on net sales.
Data presented for PXL065 at the AASLD meeting in November 2018
suggest the potential for similar efficacy with a reduced side effect
profile from pioglitazone for NASH.
On November 26, 2018, Poxel initiated Part 2 of the Phase 1a study for
PXL065. The second part of the Phase 1a study enrolled six healthy
subjects per group, with a primary objective to assess safety and
tolerability and a secondary objective to assess dose proportionality.
Following the completion of the Phase 1 program, which will include a
multiple ascending dose study, Poxel plans to advance PXL065 into a
pivotal Phase 2 program for the treatment of NASH in the fourth
quarter of 2019 or early 2020.
In September 2018, Poxel appointed Takashi Kaneko, MD, PhD, as Senior
Vice President Medical and President of Poxel Japan K.K. In addition,
Poxel also established a Japanese subsidiary in Tokyo.
Financial Statements for Full Year 2018 (IFRS Standards) Revenue
Poxel reported revenues of EUR 74.6 million for the twelve months ended
December 31, 2018, as compared with revenues of EUR 5.3 million during
the same period of 2017.
Revenues in 2018 were comprised of a portion of the EUR 36 million
upfront payment received from Sumitomo Dainippon Pharma relating to the
strategic corporate partnership announced on October 30, 2017 and a USD
35 million (EUR 28 million) upfront payment associated with the
corporate partnership announced with Roivant Sciences on February 12,
2018, net of Poxel’s required USD 25 million (EUR 20.5 million)
financial contribution to Roivant, as well as the Imeglimin Phase 3
program costs in Japan incurred during the twelve months ended December
31, 2018 that were re-invoiced to Sumitomo Dainippon Pharma. Both the
upfront payment from Sumitomo Dainippon Pharma and re-invoiced costs of
the Phase 3 Trials of IMeglimin for Efficacy and Safety
(TIMES) program are recognized according to the percentage of completion
for this program.
Poxel devotes the bulk of its resources to research and development
(R&D) activities. R&D expenses totaled EUR 54.5 million in 2018, as
compared to EUR 21.0 million in 2017. R&D expenses in 2018 mainly
reflected the EUR 46 million clinical study costs incurred for the
Imeglimin Phase 3 TIMES program over the period, which were mostly
re-invoiced to Sumitomo Dainippon Pharma. To a lesser extent, they also
reflect the clinical study costs incurred for PXL770 and PXL065, the
Company’s two clinical-stage programs for NASH. The 160% increase in R&D
expenses in 2018, as compared to 2017, is primarily driven by the Phase
3 TIMES program that was initiated in late December 2017.
R&D costs are net of the R&D Tax Credit (CIR) that resulted in income of
EUR 3.6 million in 2018, as compared to EUR 3.1 million in 2017.
General and administrative expenses totaled EUR 7.5 million in 2018, as
compared to EUR 6.2 million in 2017.
The financial income amounted to a gain of EUR 1.1 million in 2018, as
compared to a loss of EUR 0.4 million in 2017. The gain in financial
income in 2018 reflects foreign exchange fluctuations and income from
The net result for the financial period ending December 31, 2018 was a
net income of EUR 13.5 million, as compared to a net loss of EUR 22.3
million in 2017.
Condensed Income Statement
In thousand €
Net research and development expenses*
General and administrative expenses
Operating gain (loss)
Financial income (expenses)
Net income (loss)
*Net of R&D tax credit
The audit procedures have been performed and the certification
report is in process.
As of December 31, 2018, cash and cash equivalents were EUR 66.7 million
(USD 76.4 million), as compared to EUR 53.4 million (USD 64.1 million)
as of December 31, 2017.
This figure includes the upfront payment and investment proceeds
received from Roivant Sciences in February 2018 for a total amount of
USD 50 million, as well as the acquisition of the deuterated drug
candidates from DeuteRx for a USD 8 million upfront payment.
Next financial press release: Q1-turnover and cash position April
Imeglimin is the first clinical candidate in a new chemical class of
oral agents called Glimins by the World Health Organization. Imeglimin
has a unique mechanism of action ("MOA”) that targets mitochondrial
bioenergetics. Imeglimin acts on all three key organs which play an
important role in the treatment of type 2 diabetes: the liver, muscles
and the pancreas, and it has demonstrated glucose lowering benefits by
increasing insulin secretion in response to glucose, improving insulin
sensitivity and suppressing gluconeogenesis. This MOA has the potential
to prevent endothelial and diastolic dysfunction, which can provide
protective effects on micro- and macro-vascular defects induced by
diabetes. It also has the potential for protective effect on beta-cell
survival and function. This unique MOA offers the potential opportunity
for Imeglimin to be a candidate for the treatment of type 2 diabetes in
almost all stages of the current anti-diabetic treatment paradigm,
including monotherapy or as an add-on to other glucose lowering
PXL770 is a first-in-class direct adenosine monophosphate-activated
protein kinase (AMPK) activator. AMPK is a central regulator of multiple
metabolic pathways leading to the control of lipid metabolism, glucose
homeostasis and inflammation. Based on its central metabolic role,
targeting AMPK offers the opportunity to pursue a wide range of
indications to treat chronic metabolic diseases, including diseases that
affect the liver, such as non-alcoholic steatohepatitis (NASH)1.
PXL065, formerly DRX-065, is deuterium-stabilized R-pioglitazone.
Pioglitazone is the most extensively studied drug for NASH and has
demonstrated "resolution of NASH without worsening of fibrosis” in a
Phase 4 trial2. Pioglitazone is the only drug recommended for
biopsy-proven NASH patients by the Practice Guidelines published by the
American Association for the Study of Liver Diseases (AASLD) and the
European Association for the Study of the Liver (EASL).3 Pioglitazone’s
use for NASH, however, has been limited due to the PPAR?-related side
effects, which include weight gain, bone fractures and fluid retention.
Pioglitazone is a 1:1 mixture of two mirror-image compounds (R- and
S-stereoisomers) that interconvert in vivo. Using deuterium,
DeuteRx stabilized each stereoisomer and characterized their
dramatically different pharmacological properties. In in vitro studies,
PXL065 has been shown to target MPC as an inhibitor. In preclinical
models, PXL065 exhibits the anti-inflammatory activity and NASH efficacy
associated with pioglitazone with little or no weight gain or fluid
retention, side effects which are associated with the S-stereoisomer.
Based upon preclinical and Phase 1 results to date, PXL065 is expected
to exhibit a better therapeutic profile than pioglitazone for NASH.
About Poxel SA
Poxel uses its development expertise in metabolism to advance a pipeline
of drug candidates focused on the treatment of metabolic disorders,
including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We
have successfully completed the Phase 2 clinical program for our
first-in-class lead product, Imeglimin, which targets mitochondrial
dysfunction, in the U.S., Europe and Japan. Together, with our partner
Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials
of IMeglimin for Efficacy and Safety (TIMES)
program for the treatment of type 2 diabetes in Japan. Our partner
Roivant Sciences is responsible for Imeglimin’s development and
commercialization in countries outside of Poxel’s partnership with
Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a
first in class direct adenosine monophosphate-activated protein kinase
(AMPK) activator, is advancing into a Phase 2a proof-of-concept program
for the treatment of NASH. PXL770 could also have the potential to treat
additional metabolic diseases. PXL065 (deuterium-stabilized
R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in
Phase 1 and being developed for the treatment of NASH. Poxel also has
additional earlier-stage programs, including deuterated drug candidates
for metabolic, specialty and rare diseases. We intend to generate
further growth through strategic partnerships and pipeline development.
(Euronext: POXEL, www.poxelpharma.com)
Source: Smith B. K et al., (2016) Am J Physiol Endocrinol
Metab 311, E730 – E740
et al., Ann Intern Med. 2016, 165(5), 305-315)
J Hepatol. 2016, 64(6),1388-402; Hepatology 2018, 67, 328-357
View source version on businesswire.com: https://www.businesswire.com/news/home/20190321005382/en/